Replimune Group Yönetim

Yönetim kriter kontrolleri 2/4

Replimune Group CEO'su Sush Patel, Apr2024 tarihinde atandı, in görev süresi 2.17 yıldır. in toplam yıllık tazminatı $ 3.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.2% maaş ve 83.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler € 890.92K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 5.3 yıldır.

Anahtar bilgiler

Sush Patel

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi	16.23%
CEO görev süresi	2.2yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sush Patel'un ücretlendirmesi Replimune Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2025	n/a	n/a	-US$315m
Sep 30 2025	n/a	n/a	-US$310m
Jun 30 2025	n/a	n/a	-US$280m
Mar 31 2025	US$4m	US$600k	-US$247m
Dec 31 2024	n/a	n/a	-US$228m
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	US$2m	US$465k	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Tazminat ve Piyasa: Sush 'nin toplam tazminatı ($USD 3.70M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.08M ).

Tazminat ve Kazançlar: Sush şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sush Patel (55 yo)

2.2yrs

Görev süresi

US$3,697,661

Tazminat

Dr. Sushil Patel, also known as Sush, is Independent Director of Revolution Medicines, Inc. from June 16, 2022. Dr. Patel is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sushil Patel	CEO & Director	2.2yrs	US$3.70m	0.14% € 890.9k
Emily Hill	Chief Financial Officer	2.8yrs	US$1.59m	0.046% € 281.7k
Konstantinos Xynos	Chief Medical Officer	3.5yrs	US$1.62m	0.075% € 459.7k
Philip Astley-Sparke	Executive Chairman	11.4yrs	US$6.02m	1.61% € 9.9m
Andrew Schwendenman	Chief Accounting Officer & Treasurer	3.1yrs	Veri yok	0.030% € 185.5k
Shawn Glidden	Senior VP & General Counsel	1.3yrs	Veri yok	Veri yok
Camilo Garcia	Chief Human Resource Officer	1.3yrs	Veri yok	Veri yok
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	2.4yrs	Veri yok	Veri yok
Nina Aragam	Senior Vice President of Portfolio Strategy & Program Management	1.3yrs	Veri yok	Veri yok
Carolyn Trott	Senior Vice President of Quality Assurance	2.2yrs	Veri yok	Veri yok
Kari Jeschke	Senior Vice President of Regulatory Affairs	1.3yrs	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 7R8 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sushil Patel	CEO & Director	2.2yrs	US$3.70m	0.14% € 890.9k
Philip Astley-Sparke	Executive Chairman	11.4yrs	US$6.02m	1.61% € 9.9m
Joseph Slattery	Independent Director	8.7yrs	US$240.16k	0.0081% € 49.6k
Michael Goller	Independent Director	1.3yrs	US$543.13k	Veri yok
Paolo Pucci	Independent Director	6.2yrs	US$227.42k	0% € 0
Madhavan Balachandran	Independent Director	1.8yrs	US$486.71k	Veri yok
Kapil Dhingra	Independent Director	8.9yrs	US$235.16k	Veri yok
Christy Oliger	Independent Director	4.5yrs	US$234.26k	0% € 0
Dieter Weinand	Lead Independent Director	8yrs	US$264.05k	0% € 0
Veleka Peeples-Dyer	Independent Director	3yrs	US$227.66k	0% € 0

5.3yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7R8 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/12 22:28
Gün Sonu Hisse Fiyatı	2026/06/12 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Replimune Group, Inc. 13 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Replimune Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Recent updates

Now 21% overvalued after recent price rise

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Replimune Group Announces Planned RP1 BLA Resubmission Following Discussion With FDA

Now 22% undervalued after recent price drop

Replimune Group, Inc. Receives Complete Response Letter From FDA For RP1 Biologics License Application For Treatment Of Advanced Melanoma

Replimune Group, Inc. Presents Late-Breaking Abstract and Additional Posters on Rp1 At 40Th Annual Meeting of the Society for the Immunotherapy of Cancer (Sitc 2025)

Replimune Group, Inc. Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 10, 2026

Replimune Group, Inc. Highlights Acral Melanoma Data for Rp1 Plus Nivolumab At the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc

Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group, Inc. Presents New Analyses from the Ignyte Study of Rp1 Plus Nivolumab in Anti-Pd-1 Failure Melanoma At the 2025 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. to Report Q4, 2025 Results on May 22, 2025

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

CEO Tazminat Analizi

CEO